The diagnosed prevalent cases of chronic kidney disease-anemia (CKD-anemia) in the eight major markets (*8MM) are projected to increase from four million cases in 2019 to 4.5 million cases in 2029, equating to an annual growth rate (AGR) of 1.13%, according to GlobalData, a leading data and analytics company.

GlobalData’s latest report, ‘Chronic Kidney Disease-Anemia – Epidemiology Forecast to 2029’, reveals that in 2029, China will have the highest number of diagnosed prevalent cases of CKD-anemia in the 8MM at two million, whereas the UK with nearly 74,000 cases will have the lowest number of these cases. The number of diagnosed prevalent cases of CKD-anemia was higher in women than in men in the 8MM combined, though there are variations in the predominant sex by market. This is driven by differences in the diagnosed prevalent cases of CKD by sex, as well as underlying demographic differences in these markets.

Shilpa Shaji, MPH, Epidemiologist at GlobalData, comments: “Anemia may begin to develop in the early stages of CKD and it tends to worsen as CKD progresses.

“Even though CKD-anemia has been associated with substantial morbidity and mortality, with appropriate treatment modalities such as iron therapy and erythropoiesis-stimulating agents, anemia can be effectively treated and thus the patients’ quality of life can be improved.”

*8MM: The US, 5EU (France, Germany, Italy, Spain, UK), Japan and China